BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martinou E, Pericleous M, Stefanova I, Kaur V, Angelidi AM. Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. Diagnostics (Basel) 2022;12:407. [PMID: 35204498 DOI: 10.3390/diagnostics12020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Elorz M, Benito-Boilos A, Marin BA, Pérez Díaz Del Campo N, Herrero JI, Monreal JI, Tur JA, Martínez JA, Zulet MA, Abete I. Neck Circumference for NAFLD Assessment during a 2-Year Nutritional Intervention: The FLiO Study. Nutrients 2022;14. [PMID: 36501189 DOI: 10.3390/nu14235160] [Reference Citation Analysis]
2 Trifan A, Stafie R, Rotaru A, Stratina E, Zenovia S, Nastasa R, Huiban L, Cuciureanu T, Muzica C, Chiriac S, Girleanu I, Singeap AM, Sfarti C, Cojocariu C, Petrea O, Stanciu C. Screening for Liver Steatosis and Fibrosis in Patients with Inflammatory Bowel Disease Using Vibration Controlled Transient Elastography with Controlled Attenuation Parameter. J Clin Med 2022;11. [PMID: 36233826 DOI: 10.3390/jcm11195959] [Reference Citation Analysis]
3 Khurana A, Navik U, Allawadhi P, Yadav P, Weiskirchen R. Spotlight on liver macrophages for halting liver disease progression and injury. Expert Opin Ther Targets 2022. [PMID: 36202756 DOI: 10.1080/14728222.2022.2133699] [Reference Citation Analysis]
4 Kosmalski M, Drzewoski J, Szymczak-pajor I, Zieleniak A, Mikołajczyk-solińska M, Kasznicki J, Śliwińska A. Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD). Biomedicines 2022;10:2253. [DOI: 10.3390/biomedicines10092253] [Reference Citation Analysis]
5 Hochreuter MY, Dall M, Treebak JT, Barrès R. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Mol Metab 2022;:101581. [PMID: 36028120 DOI: 10.1016/j.molmet.2022.101581] [Reference Citation Analysis]
6 Rodríguez-fragoso L, Rodríguez-lópez A, Sánchez-quevedo J. Models of Hepatotoxicity for the Study of Chronic Liver Disease. Animal Models and Experimental Research in Medicine [Working Title] 2022. [DOI: 10.5772/intechopen.106219] [Reference Citation Analysis]
7 Takihata Y. Optical Diagnosis of Fatty Liver Diseases. JJSLSM 2022;43:59-64. [DOI: 10.2530/jslsm.jslsm-43_0018] [Reference Citation Analysis]
8 Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules 2022;12:824. [PMID: 35740949 DOI: 10.3390/biom12060824] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Haam J, Lee YK, Suh E, Kim Y. Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults. Diagnostics 2022;12:1199. [DOI: 10.3390/diagnostics12051199] [Reference Citation Analysis]
10 Yen PC, Chou YT, Li CH, Sun ZJ, Wu CH, Chang YF, Lu FH, Yang YC, Chang CJ, Wu JS. Hyperuricemia Is Associated with Significant Liver Fibrosis in Subjects with Nonalcoholic Fatty Liver Disease, but Not in Subjects without It. J Clin Med 2022;11:1445. [PMID: 35268536 DOI: 10.3390/jcm11051445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]